Literature DB >> 10626673

CCR5 delta32, matrix metalloproteinase-9 and disease activity in multiple sclerosis.

F Sellebjerg1, H O Madsen, C V Jensen, J Jensen, P Garred.   

Abstract

Chemokines and matrix metalloproteinases (MMPs) appear to be crucial in leukocyte recruitment to the central nervous system in multiple sclerosis (MS). CCR5 delta32, a truncated allele of the CC chemokine receptor CCR5 gene encoding a non-functional receptor, did not confer protection from MS. CCR5 delta32 was, however, associated with a lower risk of recurrent clinical disease activity. High CSF levels of MMP-9 activity were also associated with recurrent disease activity. These results directly link intrathecal inflammation to disease activity in patients with MS, suggesting that treatments targeting CCR5 or treatment with MMP inhibitors may attenuate disease activity in MS.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10626673     DOI: 10.1016/s0165-5728(99)00166-6

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  22 in total

Review 1.  Chemokines and central nervous system disorders.

Authors:  W J Karpus
Journal:  J Neurovirol       Date:  2001-12       Impact factor: 2.643

Review 2.  [Chemokine--possible new options for the treatment of multiple sclerosis].

Authors:  C Trebst; R M Ransohoff; A Windhagen; M Stangel
Journal:  Nervenarzt       Date:  2003-10       Impact factor: 1.214

3.  Investigation of substituent effect of 1-(3,3-diphenylpropyl)-piperidinyl phenylacetamides on CCR5 binding affinity using QSAR and virtual screening techniques.

Authors:  Antreas Afantitis; Georgia Melagraki; Haralambos Sarimveis; Panayiotis A Koutentis; John Markopoulos; Olga Igglessi-Markopoulou
Journal:  J Comput Aided Mol Des       Date:  2006-05-09       Impact factor: 3.686

4.  Cleavage of myelin associated glycoprotein by matrix metalloproteinases.

Authors:  Elizabeth Milward; Kee Jun Kim; Arek Szklarczyk; Thien Nguyen; Giorgia Melli; Mamatha Nayak; Deepa Deshpande; Chantel Fitzsimmons; Ahmet Hoke; Douglas Kerr; John W Griffin; Peter A Calabresi; Katherine Conant
Journal:  J Neuroimmunol       Date:  2007-12-11       Impact factor: 3.478

5.  Plasmacytoid dendritic cells in multiple sclerosis: chemokine and chemokine receptor modulation by interferon-beta.

Authors:  Latt Latt Aung; Patricia Fitzgerald-Bocarsly; Suhayl Dhib-Jalbut; Konstantin Balashov
Journal:  J Neuroimmunol       Date:  2010-09-14       Impact factor: 3.478

6.  Naturally occurring deletional mutation in the C-terminal cytoplasmic tail of CCR5 affects surface trafficking of CCR5.

Authors:  T Shioda; E E Nakayama; Y Tanaka; X Xin; H Liu; A Kawana-Tachikawa; A Kato; Y Sakai; Y Nagai; A Iwamoto
Journal:  J Virol       Date:  2001-04       Impact factor: 5.103

7.  Functional expression of chemokine receptor CCR5 on CD4(+) T cells during virus-induced central nervous system disease.

Authors:  William G Glass; Thomas E Lane
Journal:  J Virol       Date:  2003-01       Impact factor: 5.103

8.  Variants of CCR5, which are permissive for HIV-1 infection, show distinct functional responses to CCL3, CCL4 and CCL5.

Authors:  H-F Dong; K Wigmore; M N Carrington; M Dean; J A Turpin; O M Z Howard
Journal:  Genes Immun       Date:  2005-10       Impact factor: 2.676

Review 9.  The role of dendritic cells in CNS autoimmunity.

Authors:  Alla L Zozulya; Benjamin D Clarkson; Sonja Ortler; Zsuzsanna Fabry; Heinz Wiendl
Journal:  J Mol Med (Berl)       Date:  2010-03-09       Impact factor: 4.599

Review 10.  Is the CCR5 Δ 32 mutation associated with immune system-related diseases?

Authors:  Khodayar Ghorban; Maryam Dadmanesh; Gholamhossein Hassanshahi; Mohammad Momeni; Mohammad Zare-Bidaki; Mohammad Kazemi Arababadi; Derek Kennedy
Journal:  Inflammation       Date:  2013-06       Impact factor: 4.092

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.